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Abstract
Background: We observed that paclitaxel altered the pharmacokinetic properties of gemcitabine in patients
with non-small cell lung cancer (NSCLC) and limited the accumulation of gemcitabine and its metabolites in
various primary and immortalized human cells. Therefore, we classified the drug-drug interaction and the effects
of paclitaxel on deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in three NSCLC cell lines. These
enzymes are responsible for the metabolism of gemcitabine to its deaminated metabolite dFdU (80% of the parent
drug) and the phosphorylated metabolites dFdCMP, dFdCDP and dFdCTP. These metabolites appear to relate to
sensitivity and tolerability of gemcitabine based on previous animal and laboratory studies.
Methods: Three immortalized human cells representative of the most common histological subtypes identified
in patients with advanced NSCLC were exposed to the individual drugs or combinations to complete a multiple
drug effect analysis. These same cell lines were exposed to vehicle-control or paclitaxel and the mRNA levels,
protein expression and specific activity of dCK and CDA were compared. Comparisons were made using a two-
tailed paired t-test or analysis of variance with a P value of < 0.05 considered significant.
Results: The multiple drug effect analysis indicated synergy for H460, H520 and H838 cells independent of
sequence. As anticipated, paclitaxel-gemcitabine increased the number of G2/M cells, whereas gemcitabine-
paclitaxel increased the number of G0/G1 or S cells. Paclitaxel significantly decreased dCK and CDA mRNA levels
in H460 and H520 cells (40% to 60%, P < 0.05) and lowered dCK protein (24% to 56%, P < 0.05) without affecting
CDA protein. However, paclitaxel increased both dCK (10% to 50%) and CDA (75% to 153%) activity (P < 0.05).
Paclitaxel caused substantial declines in the accumulation of the deaminated and phosphorylated metabolites in
H520 cells (P < 0.05); the metabolites were not measurable in the remaining two cell lines. The ratio of dCK to
CDA mRNA levels corresponded to the combination index (CI) estimated for sequential paclitaxel-gemcitabine.
Conclusion: In summary, paclitaxel altered the mRNA levels and specific activity of dCK and CDA and these
effects could be dependent on histological subtype. More cell and animal studies are needed to further
characterize the relationship between mRNA levels and the overall drug-drug interaction and the potential to use
histological subtype as a predictive factor in the selection of an appropriate anticancer drug regimen.
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Background
Lung cancer develops in more than 200,000 people and
causes more than 160,000 deaths each year; non-small
cell lung cancer (NSCLC) is the most common type of
lung cancer. Cisplatin doublets remain the cornerstone of
treatment[1]; however, the median overall survival
remains less than one year despite multiple combinations
of third generation cytotoxic drugs and novel targeted
therapies. Anticancer drug regimens selected based on
newly identified predictive factors may lead to an
improvement in outcomes. For example, Scagliotti and
colleagues[2] demonstrated that the histological subtype
predicted clinical outcomes associated with different cis-
platin doublets.
Gemcitabine and paclitaxel is a rationale alternative drug
combination, since these anti-cancer drugs have different
mechanisms of action and only partially overlapping toxicity
and these drugs are among the most active anti-cancer drugs
for NSCLC [3,4]. Gemcitabine is a fluorinated pyrimidine
analog that causes masked chain termination and inhibits
ribonucleotide reductase (RNR) [5]. It induces a G0/G1 or S
phase arrest and triggers apoptosis in both hematological
malignancies and solid tumors. Gemcitabine undergoes
sequential intracellular phosphorylation by deoxycytidine
kinase (dCK) and other nucleoside kinases to an active
metabolite, difluorodeoxycytidine triphosphate (dFdCTP).
The triphosphate is incorporated into DNA and inhibits
DNA synthesis by stopping chain elongation. The diphos-
phate metabolite (dFdCDP) potentiates the incorporation of
the dFdCTP into DNA by inhibiting RNR. This reduces the
intracellular accumulation of deoxycytidine triphosphate
(dCTP) and promotes the incorporation of dFdCTP into
DNA. Reducing the intracellular accumulation of dCTP also
inhibits deoxycytidine monophosphate deaminase and
helps to maintain the nucleotide pool needed to form the
phosphorylated metabolites. Essentially, gemcitabine poten-
tiates its own cytotoxicity. The accumulation of the triphos-
phate and alterations in either dCK or RNR are associated
with either sensitivity or resistance to gemcitabine in various
cell lines and animal models [6-10].
Gemcitabine also undergoes intracellular and extracellu-
lar metabolism by cytidine deaminase (CDA) to pur-
ported inactive metabolite, difluorodeoxyuridine (dFdU).
The deamination pathway accounts for at least 77% of the
administered dose with about 5% of the parent drug gem-
citabine excreted unchanged in the urine within the first
six hours [11]. Reduced deamination contributes to mye-
losuppression based on a recent study conducted in a
mouse model [12].
Paclitaxel is a natural product isolated form a pacific yew
tree that induces a G2/M phase arrest by binding and sta-
bilizing microtubules in solid tumors [13]. It is metabo-
lized by cytochrome P450 enzymes to two potentially
active metabolites. The most common toxicities include
myelosuppression and peripheral neuropathy.
Clinical studies incorporating combinations of gemcitab-
ine and paclitaxel were initiated more than 10 years ago.
Many of these clinical trials indicated paclitaxel-gemcitab-
ine provides patients with improved response rates com-
pared to gemcitabine or paclitaxel alone, but further
examination of these studies revealed that the combina-
tion provides only marginal benefit compared to each
agent alone and appears inferior compared to other com-
binations [4,14,15]. However, this combination could
prove beneficial to some patients if appropriately selected
based on histological subtype or molecular markers. Our
data supports that paclitaxel reduces the volume of distri-
bution and systemic clearance of gemcitabine and paclit-
axel limits the uptake and metabolism of the gemcitabine
in primary and immortalized human cells [16,17]. In the
present study, we further investigated this combination
and the effects of paclitaxel on the mRNA levels, protein
expression and specific activity of dCK and CDA based on
our observations that paclitaxel reduces the systemic clear-
ance in humans and the accumulation of the metabolites
in the laboratory. For this purpose, we treated three sepa-
rate immortalized human NSCLC cell lines obtained from
patients diagnosed with advanced disease that represent
the more common histological subtypes.
Methods
Chemicals
Gemcitabine (Gemzar®; 2',2'-difluoro- 2'-deoxycytidine;
dFdC) was a generous gift from Eli Lilly and Company
(Indianapolis, IN) and dissolved in sterile distilled water.
Paclitaxel was purchased from Sigma-Aldrich Company
(St. Louis, MO) and dissolved in 0.1% acetic acid in meth-
anol. Radiolabeled chlorodeoxyadenosine (8-3H-CdA,
7.8 Ci/mmol) was purchased from Moravek (Brea, CA).
All other chemicals were of analytical grade.
Cell culture
The NSC large cell lung carcinoma H520 cell line
(mutant-p53) was provided by Dr. William T. Beck (Uni-
versity of Illinois, Chicago, Illinois, USA). The NSC H460
squamous carcinoma cell line (wild-type p53) and H838
adenocarcinoma cell line (wild-type p53) were obtained
from the American Type Culture Collection (Manassas,
Virginia, USA). The cells were grown in monolayers and
maintained in exponential growth in RPMI-1640 medium
containing 2 mM L-glutamine supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin (10,000 U
penicllin per ml)-streptomycin (10 mg of streptomycin
per ml) at 37°C at 5% CO2. The medium was further sup-
plemented with insulin (Gibco Life Technologies, Grand
Island, New York, USA) for H520 cells.Journal of Experimental & Clinical Cancer Research 2009, 28:76 http://www.jeccr.com/content/28/1/76
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Growth inhibition assay
Growth inhibition was determined using a dye exclusion
assay with trypan blue staining followed by a cell count
using a hemocytometer [18]. Briefly, ~3.5 × 105 cells were
seeded in duplicate in 6-well flat bottom plates. After 24
hours, the cells were treated with vehicle-control, gemcit-
abine (ranged from 1 to 15,000 nM) or paclitaxel (ranged
from 1 to 3,000 nM) for 24 hours. The fraction of affected
cells and unaffected cells for the individual drugs was cal-
culated compared to cells exposed to vehicle-control. The
IC50 values were determined using linear regression anal-
y s i s  w i t h  t h e  a i d e  o f  C a l c u S y n  s o f t w a r e  ( v .  2 ,  B i o s o f t ,
Cambridge, UK).
A multiple drug effect analysis was completed to predict the
likely drug-drug interaction based on the principles of
Chou and Talalay [19]. The combination index (CI) for
each fraction affected was simulated and for the final eval-
uation, the averaged CI at 0.50, 0.75, 0.90 and 0.95 fraction
affected was determined [20]. Briefly, ~1 × 106 cells were
seeded in duplicate in 60 mm dishes. After 24 hours, the
cells were treated with sequential gemcitabine → paclitaxel
and paclitaxel → gemcitabine at five different concentra-
tions of a constant ratio based on the ratio of the observed
IC50 values of each cell line. The cells were exposed to each
drug for 24 hours; the medium containing the first drug
was removed, the cells were washed with phosphate buff-
ered saline, then medium containing the second drug was
added to the cells. The total culture time was 72 hours. A CI
< 0.3, 0.3–0.7, 0.7–0.9, 0.9–1.1, 1.1–1.45, 1.45–3.3 and
>3.3 indicates highly synergistic, synergistic, moderate to
slight synergistic, nearly additive, slight to moderate antag-
onistic, antagonistic; strong antagonistic, respectively (Cal-
cuSyn software, v. 2, Biosoft, Cambridge, UK).
Flow cytometry
Flow cytometric measurements were performed after
staining the cellular DNA content with propidium iodide
to determine the cell cycle distribution and apoptosis fol-
lowing treatment with sequential gemcitabine → paclit-
axel or paclitaxel → gemcitabine. Briefly, ~1 × 106 cells
were plated in 60 mm dishes and allowed to attach over-
night. After treatment with sequential gemcitabine →
paclitaxel or paclitaxel → gemcitabine as described for the
determination of the CI, the cells were harvested and sus-
pended in a propidium iodide solution (Sigma-Aldrich
Co.) as described previously [21] and filtered in 5 ml
round bottom tube with cell-strainer cap (BD Falcon).
The cell cycle analysis was performed on a Beckman-Coul-
ter EPICS Elite ESP flow cytometer (Hialeah, Florida,
USA) using the Multicycle AV program (v. 3, Phoenix
Flow Systems, San Diego, Calfornia, USA).
dCK and CDA enzyme specific activity
The effect of paclitaxel on dCK and CDA enzyme specific
activity was measured after exposing ~20–30 × 106 cells
(seeded in duplicate in 100 mm dishes) to either vehicle-
control or paclitaxel at the observed IC50 value for 24
hours. Cells were manually harvested and counted. Total
protein was quantified using BCA protein kit (Pierce Bio-
technology, Rockford, Illinois, USA)
dCK activity was analyzed using radiolabeled chlorode-
oxyadenosine (CdA) as previously described [22,23].
Briefly, the crude cellular extract was suspended in Tris-
HCl buffer and mixed with CdA 256.5 μM plus [8-3H]-
CdA (128 μM, specific activity 0.19 μCi/nmol) as sub-
strate. The enzymatic reaction was incubated for 1 hour at
37°C. Enzyme activities were expressed as nmol product
formed per hour per mg protein or 106 cells.
The CDA activity was measured using a spectrophotomet-
ric method as described by Dr. Vincenzetti [24]. The crude
cellular extract was suspended in a Tris-HCl buffer and
freeze-thawed rapidly three times. The extract was subse-
quently centrifuged for 15 minutes at 12,000 g and the
resulting supernatant was suspended in the Tris-HCl
buffer. The enzymatic reaction was performed in a 96 well
UV-Vis transparent plate (BD Falcon) and initiated with
the addition of the substrate cytidine (167 μM). The mix-
ture was incubated at 37°C and the change in absorbance
at 282 nm was measured for 10 minutes using a Synergy
HT multidetection microplate reader (Biotek, Winooski,
Vermont, USA). Enzyme activities were expressed as
mmol substrate consumed per minute per mg protein or
106 cells.
Gene expression
Total RNA and protein was extracted form cells exposed to
vehicle-control or paclitaxel at varying concentrations for
24 hours using the PARIS™ kit (Ambion, Austin, Texas,
USA) according to manufacturer's instructions. Total RNA
was treated with TURBO DNA free (Ambion) to remove
DNA contamination and the concentration was measured
at 260 nm. The total RNA was reverse transcribed using
random primers and the High Capacity cDNA reverse
transcription kit (Applied Biosystems) per the manufac-
turer's product information.
Table 1: Sensitivity of solid tumor cells lines to gemcitabine and 
paclitaxel
Cell line/Exposure H460 H520 H838
IC-50 Gemcitabine (nM)
24 h 6.7 1541.1 72.8
IC-50 Paclitaxel (nM)
24 h 178.0 241.6 7.2
The IC-50 is defined as the concentration that causes 50% inhibition 
of cell growth after exposure to either gemcitabine 24 h or paclitaxel 
24 h. Growth inhibition was determined using a direct cell count and 
the fraction affected was averaged from three independent 
experiments with six replicates to calculate the IC-50 using CalcuSyn 
(v 2.0, Biosoft).Journal of Experimental & Clinical Cancer Research 2009, 28:76 http://www.jeccr.com/content/28/1/76
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Table 2: Combination index of solid tumor cell lines for gemcitabine and paclitaxel
Exposure/Cell line H460 H520 H838
PAC 24 h > GEM 24 h 0.58 ± 0.84 0.006 ± 0.010 0.63 ± 0.03
Predicted Interaction Synergistic Highly Synergistic Synergistic
GEM 24 h > PAC 24 h 0.60 ± 0.91 0.34 ± 0.41 0.50 ± 0.57
Predicted Interaction Synergistic Synergistic Synergistic
Mean (± standard deviation) CI values after exposure to paclitaxel for 24 hours followed by gemcitabine for 24 hours or gemcitabine for 24 hours 
followed by paclitaxel 24 hours. The mean CI values represent the average of the CI at the fraction affected of 0.50, 0.75, 0.90 and 0.95. Cells were 
seeded in 6-well flat bottom plates in duplicate at 5 separate concentrations of constant ratio based on the ratio of the observed IC-50 values. 
Three independent counts were conducted for each well with a total of six replicates and the CI was determined using an algebraic estimation 
algorithm with the aide of CalcuSyn (v 2.0, Biosoft).
Combination index values and fraction of cells affected for three non-small cell lung cancer cell lines exposed to paclitaxel fol- lowed by gemcitabine or gemcitabine followed by paclitaxel at 24 hours interval with a total culture time of 48 h Figure 1
Combination index values and fraction of cells affected for three non-small cell lung cancer cell lines exposed 
to paclitaxel followed by gemcitabine or gemcitabine followed by paclitaxel at 24 hours interval with a total 
culture time of 48 h. (a) H460, squamous cell carcinoma; (b) H838, adenocarcinoma carcinoma and (c) H520, large cell car-
cinoma.
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The human hypoxanthine phosphoribosyltransferase
(HPRT) gene was selected as an endogenous control after
assessing the gene expression of 11 potential controls
using the TaqMan human endogenous control plate
(Applied Biosystems). HPRT  produced  ΔCT values that
deviated little from zero, indicating relative to other can-
didate controls, that the expression of HPRT remains rela-
tively consistent across the samples tested regardless of
type of cells or treatment. Primers and probes for the dCK
and  CDA  were from Applied Biosystems Assay on-
Demand Gene expression products. The cDNA was ampli-
fied by quantitative real-time PCR in triplicate using the
following thermal profile: an initial incubation at 50°C
for 5 minutes, followed by 40 cycles of denaturation at
95°C for 15 seconds followed by annealing and extension
at 60° for 1 minute with the Applied Biosystems 7900 HT
sequence detection system. The quantitation of gene
expression was performed relative to the calibrator (vehi-
cle-control cells) using the ΔΔCT calculation for dCK and
the relative standard curve calculation for CDA. A valida-
tion experiment was performed that demonstrated the
efficiencies were 0.08 for dCK and 1.1 for CDA. To use the
ΔΔCT calculation, the efficiencies should be less than 0.1.
Western blot
Total protein was separated on a 12% SDS-polyacryla-
mide gel for dCK or a 14% SDS-polyacrylamide gel for
CDA and transferred to a polyvinylidene diflouride
(PVDF) membrane [25,26]. The membrane was probed
with the either dCK-pep antibody (obtained from Dr.
Hatzis) at a 1:4,000 dilution or CDA antiserum (obtained
from Dr. Momparler) at a 1:175 dilution followed by
incubation with horseradish peroxidase-conjugated anti-
rabbit IgG (Pierce, Rockford, Illinois, USA). The mem-
brane was also probed with β-actin (Sigma-Aldrich Co) at
1:12,000 dilution, followed by incubation with horserad-
ish peroxidase-conjugated anti-mouse IgG (Calbiochem,
San Diego, California, USA) antibody as an endogenous
control. Immuncomplexes were visualized by SuperSignal
West Pico chemiluminescent substrate kit (Pierce, Rock-
ford, IL) and the band density was semi-quantitated using
ImageJ (v. 1.38×, http://rsb.info.nih.gov/ij/index.html)
software.
Analysis of gemcitabine, difluorodeoxyuridine and the 
phosphorylated metabolites
The cells were treated with vehicle-control or paclitaxel at
the observed IC-50 value for 24 hours followed by gemcit-
abine at the observed IC-50 value for 24 hours. The cell
medium and pellet were manually harvested and stored at
-80°C until analysis. The phosphorylated metabolites
were analyzed by Dr. Hilde Rosing within the Department
of Pharmacy and Pharmacology at the Netherlands Can-
cer Institute/Slotervaart Hospital in Amsterdam, Nether-
lands using their previously described LC-MS method
[27]. The lower limit of quantitation was 26.8 nM for the
monophosphate, 27.0 nM for the diphosphate and 2.53
nM for the triphosphate.
Gemcitabine and its deaminated metabolite dFdU were
analyzed in our laboratory using our previously published
method with hexanes used to wash the culture medium
[28]. The lower limit of quantitation was 0.25 μM for both
gemcitabine and dFdU.
Statistical analysis
All results are expressed as the mean ± the standard devia-
tion of three independent experiments conducted in at
least triplicate. Statistical significance was determined by
a two sided paired t test or analysis of variance and the
level of significance was set at P < 0.05 a priori. A correla-
tion analysis was conducted to determine the relationship
between the ratio of dCK to CDA mRNA levels and com-
bination index.
Results
Effects of gemcitabine and paclitaxel on cell viability
Table 1 summarizes the sensitivity of H460, H520 and
H838 cell lines to gemcitabine and paclitaxel. H460 cells
were the most sensitive to gemcitabine and H838 cells
were the most sensitive to paclitaxel. From these data, the
ratio of the observed IC-50 values of gemcitabine to pacl-
itaxel was determined and used to perform the multiple
drug effect analysis.
Effects of paclitaxel on dCK and CDA Figure 2
Effects of paclitaxel on dCK and CDA. Mean (± standard 
deviation) relative mRNA levels of dCK and CDA to HPRT in 
paclitaxel treated cells compared to the mRNA levels of dCK 
and CDA to HPRT in vehicle control treated cells (set to the 
value of 1) from three independent experiments. The cells 
were treated with paclitaxel at the observed IC-50 value for 
24 hours.
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Table 2 summarizes the average CI for these cell lines for
0.50, 0.75, 0.90 and 0.95 fraction affected and Figure 1
illustrates the CI vs. the fraction of affected cells exposed
to sequential paclitaxel-gemcitabine or gemcitabine-pacl-
itaxel. The interaction was classified as synergistic for all
three cell lines independent of sequence based on the
average CI, but the individual curves suggest that pre-
dicted interaction may be dependent on the drug concen-
tration. For example, the CI predicts additivity or
antagonism as the fraction affected approaches 100% in
H460 cells.
Comparing the fraction affected indicates a sequence
dependent effect in two of the three cell lines (H460,
H838); the sequence gemcitabine-paclitaxel was favored
in these two cell lines compared to the sequence paclit-
axel-gemcitabine (paclitaxel-gemcitabine vs. gemcitabine-
paclitaxel, P < 0.05). However, the percentage of apop-
totic cells largely favors sequential paclitaxel-gemcitabine
with significantly more apoptosis found in H838 cells (P
< 0.01).
Effects of gemcitabine and paclitaxel on cell cycle 
distribution
Flow cytometric measurements were completed to com-
pare the effects of sequential paclitaxel-gemcitabine and
gemcitabine-paclitaxel on the cell cycle distribution. Table
2 summarizes the effects of gemcitabine and paclitaxel on
dCK and CDA protein expression in non-small cell lung cancer cell lines Figure 3
dCK and CDA protein expression in non-small cell lung cancer cell lines. (a) A representative Western immunoblot 
of crude cellular extracts from H460 (lane 1,2), H520 (lane 3,4), H838 (lane 5,6) and AG6000 (A2780 variant without dCK, 
lane 7). The odd lanes were treated with vehicle-control and the even lanes were treated with paclitaxel at the observed IC50 
value for 24 hours. (b) The mean (± standard deviation) relative protein levels of dCK to β-actin after exposure to paclitaxel at 
the observed IC-50 value for 24 hours compared to vehicle-control (set to the value of 1) from three independent experi-
ments. (c) A representative Western immunoblot of crude cellular extracts from H460 (lane 1,2), H520 (lane 3,4), and H838 
(lane 5,6). The odd lanes were treated with vehicle-control and the even lanes were treated with paclitaxel at the observed 
IC50 values for 24 hours. (d) The mean (± standard deviation) relative protein levels of CDA to β-actin treated with paclitaxel 
at the observed IC-50 value for 24 hours compared to relative protein levels of CDA to β-actin treated with vehicle-control 
(set to the value of 1) from three independent experiments.
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cell cycle distribution. These cells were exposed to sequen-
tial gemcitabine-paclitaxel or the reverse sequence. As
anticipated, paclitaxel-gemcitabine produced a sequence
dependent increase in the number of G2/M cells as noted
in H520 cells (paclitaxel-gemcitabine vs. gemcitabine-
paclitaxel, P < 0.05) and gemcitabine-paclitaxel produced
an increase in the number of G0/G1 cells as noted in
H520 cells (P < 0.05).
Effects of paclitaxel on gene expression, protein and 
activity of dCK
The effects of paclitaxel on dCK mRNA levels were meas-
ured by quantitative RT-PCR using ΔΔCT method (Figure
2). The mRNA expression was significantly decreased in
paclitaxel vs. vehicle-control treated H460 (52%, P <
0.05) and H520 (39%, P < 0.05) cells. The mRNA expres-
sion was relatively unchanged in the H838 cells.
The effects of paclitaxel on dCK protein were measured by
Western immunoblot analysis (Figure 3). The protein
expression decreased by 24 to 56% in all cell lines, but the
decrease was only statistically significantly lower in pacli-
taxel-treated H460 cells compared to vehicle-control
treated cells (P < 0.05).
The enzyme specific activities of dCK are summarized in
Table 3. The cells were exposed to vehicle-control or pacl-
itaxel at the observed IC-50 value determined in the spe-
cific cell line. Basal dCK activity was highest in H838 cells
and lowest in H460 cells. The mean activity increased 10
to 50% in all of the cell lines, but the increase in activity
was only statistically significantly higher in H460 and
H520 cells treated with paclitaxel compared to vehicle-
control (P < 0.05).
Effects of paclitaxel on gene expression, protein and 
activity of CDA
The effects of paclitaxel on CDA mRNA levels were meas-
ured by quantitative RT-PCR using the relative standard
curve method (Figure 2). As measured for dCK mRNA lev-
els, the mRNA levels was statistically significantly
decreased in H460 (52%, P < 0.05) and H520 (59%, P <
0.05) cells treated with paclitaxel compared to vehicle-
control. The mRNA levels were relatively unchanged in
the H838 cells.
The effects of paclitaxel on CDA protein were measured by
Western immunoblot analysis. The protein expression
was unchanged in all three cell lines after treatment with
paclitaxel at the observed IC-50 value for 24 hours com-
pared to vehicle-control (Figure 3).
The activities of CDA are summarized in Table 4. The cells
were exposed to vehicle-control or paclitaxel at the observed
IC-50 value determined in the specific cell line. Basal CDA
activity was highest in H520 cells and lowest in H838 cells.
The mean activity increased in all three cell lines 75% to
153%, but the increase in activity was only statistically signif-
icantly higher in H520 cells treated with paclitaxel compared
to cells treated with vehicle-control treated cells (P < 0.001).
Effects of paclitaxel on the accumulation of the 
phosphorylated and deaminated metabolites
The deaminated and phosphorylated metabolites were
measurable in only the H520 cells within the medium
Table 3: Effects of paclitaxel on deoxycytdine kinase and cytidine 
deaminase activity in solid tumor cell lines
Exposure/Cell line H460 H520 H838
Control
%G0 + G1 66 ± 1.2 62 ± 2.1 80 ± 7.5
%G2 + M 8.0 ± 1.4 13.2 ± 1.0 4.8 ± 2.4
%S 26 ± 1.7 25 ± 1.3 15 ± 5.1
% Apoptosis 7.5 ± 1.7 3.2 ± 0.6 9.7 ± 7.2
PAC 24 h > GEM 24 h
%G0 + G1 17 ± 11 36 ± 6.4 23 ± 6.0
%G2 + M 25 ± 7.8 44 ± 6.4a 15 ± 4.7
%S 58 ± 3.2 20 ± 2.3 41 ± 1.0
% Apoptosis 8.6 ± 5.1 2.1 ± 1.4 4.6 ± 1.0
GEM 24 h > PAC 24 h
%G0 + G1 13 ± 6.0 62 ± 4.9a 23 ± 10.3
%G2 + M 30 ± 1.7 9.7 ± 1.6 9.8 ± 8.0
%S 56 ± 7.7 28.8 ± 3.5 43 ± 1.6
% Apoptosis 7.0 ± 4.9 3.4 ± 2.2 0.87 ± 0.05a
Mean (± standard deviation) percentage of cells in each phase of the 
cell cycle after exposure to vehicle control or sequential paclitaxel → 
gemcitabine or gemcitabine → paclitaxel at 24 hours intervals. The 
mean represents three independent experiments with each 
experiment conducted in at least triplicate.
a P < 0.05, paclitaxel vs. vehicle-control treated cells
Table 4: The effects of paclitaxel on deoxycytdine kinase and 
cytidine deaminase activity and gene expression in solid tumor 
cell lines
Cell line H460 H520 H838
Deoxycytidine kinase (dCK)
Control 0.46 ± 0.12 1.23 ± 0.12 2.44 ± 1.56
Paclitaxel 0.69 ± 0.14 1.67 ± 0.25 2.60 ± 0.46
Fold change 1.5 1.4a 1.1
Cytidine deaminase (CDA)
Control 11.8 ± 3.4 18.2 ± 10.5 4.1 ± 2.1
Paclitaxel 27.0 ± 16.1 31.9 ± 11.1 10.4 ± 6.8
Fold change 2.3 1.8a 2.5
Mean (± standard deviation) of the activity of deoxycytidine kinase 
(nmol per hour per 106 cells) or cytidine deaminase (pmol per minute 
per 106 cells) after exposure to vehicle-control or paclitaxel for 24 
hours. The mean represents three independent experiments with 
each experiment conducted in at least triplicate. The fold change 
represents the mean activity after exposure to paclitaxel divided by 
the mean activity after exposure to vehicle-control.
a P < 0.05 or P < 0.001, paclitaxel vs control-treated cellsJournal of Experimental & Clinical Cancer Research 2009, 28:76 http://www.jeccr.com/content/28/1/76
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and the cellular pellet, respectively (Figure 4). The accu-
mulation of these metabolites was substantially decreased
by paclitaxel in this cell line. The accumulation of the
diphosphate exceeded the accumulation of the mono-
and triphosphate. The triphosphate decreased by about
75%, the diphosphate decreased by about 87% (paclitaxel
vs. vehicle control, P < 0.05) and the monophosphate
decreased by about 37% in the H520 cells. The accumula-
tion of the deaminated metabolite also decreased in the
H520 cells (27%). Consistent with these substantial
changes found in the metabolite accumulation (both the
phosphorylated and deaminated metabolites), gemcitab-
ine increased by 60% (P < 0.001) in paclitaxel-treated
H520 cells vs. vehicle-control treated cells. This cell line
was least sensitive (as noted by the IC-50 values) to gem-
citabine and therefore, were treated with higher concen-
trations of gemcitabine which resulted in metabolite
concentrations that exceeded the limits of quantitation.
Relation between deoxycytidine kinase, cytidine 
deaminase and cell growth
A relationship between the ratio of the mRNA levels of
dCK to CDA and the CI estimated for the sequential pacl-
itaxel → gemcitabine was observed. The cells were treated
with gemcitabine and paclitaxel at the observed IC-50 val-
ues of each drug at 24 hour intervals for a total culture
time of 72 hours as described above. A CI < 1 was
observed in H838 and H520 cells with a ratio of dCK to
CDA > 1 and a CI = 1 was observed in H460 cells with a
ratio of dCK to CDA = 1. Furthermore, the ratio of the
mRNA levels strongly correlated with the combination
index when examining an expanded concentration range
in H838 cells (r = 0.90, p < 0.05). This observed relation-
ship indicates that dCK mRNA levels are higher compared
to CDA mRNA levels in cells in which the CI predicts syn-
ergism. A relationship between dCK activity or expression,
CDA activity or expression, or other ratios with the CI
were not observed.
Discussion
We previously identified a possible drug-drug interaction
between gemcitabine and paclitaxel; paclitaxel reduced
the volume of distribution and systemic clearance of gem-
citabine in humans and decreased the transport and accu-
mulation of gemcitabine and its metabolites in primary
and immortalized cells. These data appear to suggest that
paclitaxel compromises the metabolism and transport of
gemcitabine [16,17]. In this study, we found that paclit-
axel-gemcitabine demonstrates synergy in three immor-
talized cells lines when the individual drug concentrations
exceed the IC50 values of each individual drug, although
paclitaxel substantially reduced the mRNA levels of dCK
and CDA, the two enzymes responsible for the metabo-
lism of gemcitabine to its key metabolites. We focused on
the effect of paclitaxel on the metabolism of gemcitabine
at this time based on previous data that indicate dCK
activity corresponds to the sensitivity of murine tumors
and human tumor xenografts to gemcitabine and CDA
activity corresponds to myelosuppression in children
[8,12].
The effect of paclitaxel on the accumulation of gemcitabine,  diflourodeoxyuridine (dFdU) and the phosphorylated metab- olites of gemcitabine Figure 4
The effect of paclitaxel on the accumulation of gem-
citabine, diflourodeoxyuridine (dFdU) and the phos-
phorylated metabolites of gemcitabine. The cells were 
treated with vehicle-control or paclitaxel at the observed IC-
50 value for 24 hours followed by gemcitabine at the 
observed IC-50 value for 24 hours. The cell medium was col-
lected and the cells manually harvested by a cell scraper; the 
medium and cells were stored at -80°C until analysis. Gem-
citabine and its metabolites were below the limits of quanti-
tation in two of the three cell lines. The accumulation of 
phosphorylated metabolites within the cells was measurable 
in (a) H520 cells and the accumulation of gemcitabine and 
dFdU in the medium were measurable in (b) H520 cells. The 
diphosphate levels were significantly lower in paclitaxel 
treated cells compared to vehicle-control treated cells (P < 
0.05). Gemcitabine levels were significantly higher in paclit-
axel treated cells compared to vehicle-control treated cells 
(P < 0.001).
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We selected three solid tumor cell lines representing the
most common histologies in patients diagnosed with
advanced NSCLC; these immortalized cell lines were
acquired from patients with advanced disease (H460,
squamous cell carcinoma; H520, large cell carcinoma;
and H838, adenocarcinoma). The multiple drug effect
analysis indicates this interaction is largely independent
of culture conditions or sequence; but a sequence depend-
ent effect was noted regarding the fraction of affected cells
with the gemcitabine-paclitaxel sequence favored in two
of the three cell lines (H460, H838). Our results for the
H460 cells compare well with a previous report in which
the CI for sequential paclitaxel-gemcitabine and gemcit-
abine-paclitaxel was reported for similar exposure [20].
Although our data supports administering gemcitabine
before paclitaxel based on the fraction affected, the per-
centage of apoptotic cells largely favors paclitaxel before
gemcitabine consistent with the current administration of
this combination to patients with advanced breast, lung
or ovarian cancers. Dr. Kroep similarly concluded that
sequential paclitaxel-gemcitabine was favored based on
an increase in apoptosis compared to the reverse sequence
[20]. As anticipated, paclitaxel increased the number of
G2/M cells and gemcitabine increased the number of G0/
G1 or S cells. A relationship between cell cycle distribu-
tion and the CI was not observed.
Only one other study explored possible effects of paclit-
axel on dCK, but no other studies have described the
effects of paclitaxel on CDA [20]. Kroep et al[20] reported
that paclitaxel increased the accumulation of the triphos-
phorylated metabolite in H460 cells, but that dCK activity
was not changed. Our findings indicate that paclitaxel
increased dCK activity in all three cells lines including
H460 cells and that the changes were only statistically sig-
nificantly higher in the H520 cells. However, the mRNA
levels were significantly reduced in two cells lines, H460
and H520, with relatively substantial decreases in protein.
It is unclear why the reported outcomes are different in
these studies, but the differences may be dependent on
allosteric regulation governed by differences in substrate
concentrations of dCTP. Additional data in breast and
ovarian adenocarcinoma cells lines from our laboratory
also show no change in mRNA levels and an increase in
specific activity; these data are comparable to the changes
observed in the lung adenocarcinoma cell line.
We also indicate that paclitaxel caused similar changes in
the expression and activity of CDA. Paclitaxel substan-
tially reduced mRNA levels in the same two cells lines in
which paclitaxel decreased mRNA levels of dCK. Further-
more, CDA protein expression appears relatively
unchanged by paclitaxel, but specific activity appears sub-
stantially increased. We also observed similar changes in
CDA mRNA, protein and activity in two additional aden-
ocarcinoma cell lines (breast and ovarian). We believe
that our data collectively indicates that these changes may
be dependent on the histological subtype, since we only
observed changes in large cell and squamous cell carci-
noma, and not adenocarcinoma cell lines. These experi-
ments will need to be repeated in additional cell lines
representative of these histologies to confirm our find-
ings.
The accumulation of gemcitabine and its metabolites
were only measurable in H520 cells. Most likely, it is
because this cell line was least sensitive to gemcitabine (as
noted by higher IC50 values) and therefore, the accumu-
lation of these metabolites exceeded the lower limits of
quantitation of the assay. Of interest, this cell expresses
mutant p53, whereas the remaining two cell lines express
wild-type p53. The noted differences in sensitivity to gem-
citabine could be explained, in part, by p53 expression,
since gemcitabine inhibits apoptosis dependent on p53
status [29]. Furthermore, the changes in the metabolite
accumulation in H520 cells appears to reflect changes in
dCK and CDA mRNA levels in these cell lines and further
supports our findings that the CI corresponds to the ratio
of dCK to CDA mRNA levels. The ratio of dCK to CDA
mRNA levels could be a useful maker of response in
humans. Of note, we observed that the accumulation of
gemcitabine and its phosphorylated and deaminated
metabolites were unchanged in an ovarian adenocarci-
noma cell line; the lack of change in the accumulation of
the parent drug and the metabolites in this cell line are
consistent with the lack of changes in mRNA levels. This
cell line also expresses mutant p53 and demonstrated IC-
50 values similat to the IC-50 values of the H520 cell line
[30]. Lastly, the accumulation of the diphosphate
exceeded the accumulation of the triphosphate in the
H520 cells treated with vehicle-control followed by gem-
citabine. The triphosphate has been identified as the dom-
inant metabolite. We used lower concentrations than
those shown to maximize the accumulation of the tri-
phosphate and harvested the cells and medium after the
time of the maximal accumulation of the triphosphate
and we believe these differences may explain, in part, why
the diphosphate was the dominant metabolite in this cell
line [31].
More studies are needed to examine the relationship of
this ratio of mRNA with the CI in cell models and with
response rates and survival in animal models before
examining the clinical utility of this marker. Experimental
conditions, including drug concentrations, treatment
duration and cofactors, can sometimes limit the transla-
tion of laboratory findings to humans. But we demon-
strated similar outcomes in the laboratory when the cells
were treated with shorter durations comparable to the
length of infusions in human and higher concentrations
that can be easily achieved in the plasma of humans after
a standard dose (data not shown). Therefore, we believe itJournal of Experimental & Clinical Cancer Research 2009, 28:76 http://www.jeccr.com/content/28/1/76
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is important to continue characterizing the effects of pacl-
itaxel on the expression and activity of these proteins and
determine how these modifications impact the pharma-
cokinetic properties and clinical outcomes in an animal
model.
In summary, paclitaxel appears to modulate two key
enzymes involved in the metabolism of cytidine ana-
logues, including gemcitabine, and plays an integral role
in the salvage of pyrimidine analogues. The effects on
mRNA levels may be dependent on histological subtype
(i.e. the effects were only noted in large cell and squamous
cell carcinomas, not adenocarcinomas), but the studies
need to be repeated in additional cell lines representative
of the three distinct histologies. The changes in enzyme
activity, in light of decreased or minimal changes in gene
or protein expression, appear contradictory and could be
dependent on experimental conditions (such as treatment
duration, cofactors, etc), but it is possible to increase activ-
ity of these enzymes with minimal changes in protein
concentrations by altering post-translational modifica-
tions (i.e. increasing nuclear localization). Of note, we
obtained comparable results when exposing the cells to
shorter duration (1–3 hours) or clinically achievable con-
centrations (3 to 15 μM) suggesting that these findings are
likely independent of the experimental conditions [30].
At this time, changes in mRNA levels appear to be the pre-
dominant effects, since the ratio of dCK to CDA mRNA
levels corresponding to the CI, a mathematical model
commonly uses to conduct a multiple drug effect analysis,
and the changes in accumulation of the deaminated and
phosphorylated metabolites are in concert with the
changes in mRNA levels.
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